HKSE:02563 (China)
Â
Ordinary Shares - Class H
HK$
3.4
-0.15 (-4.23%)
Aug 6
Business Description
Beijing Biostar Pharmaceuticals Co Ltd
ISIN : CNE100006NB3
Share Class Description:
HKSE:02563: Ordinary Shares - Class HTotal Employee Number:
134Compare
Compare
Traded in other countries / regions
02563.Hong Kong IPO Date
2024-10-31Description
Beijing Biostar Pharmaceuticals Co Ltd is a synthetic biology-driven biopharmaceutical company committed to developing drugs in oncology. It has developed three core technology platforms that focus on the R&D of microbial metabolite new drugs. Its Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of its product portfolio. The company's current clinical trials and programs of the Core Product and product candidates cover indications of advanced breast cancer, advanced non-small cell lung cancer, neoadjuvant for breast cancer, gastric cancer, esophageal cancer, breast cancer brain metastasis, lung cancer brain metastasis, glioblastoma, and other solid tumors.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 231.26 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 5.11 | |||||
Beneish M-Score | 1.54 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 7.4 | |||||
3-Year EPS without NRI Growth Rate | 7.8 | |||||
3-Year FCF Growth Rate | -11.5 | |||||
3-Year Book Growth Rate | -8.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 265.97 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 20.77 | |||||
9-Day RSI | 32.17 | |||||
14-Day RSI | 39.53 | |||||
3-1 Month Momentum % | -18.22 | |||||
6-1 Month Momentum % | -0.54 | |||||
12-1 Month Momentum % | -54.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.33 | |||||
Quick Ratio | 7.67 | |||||
Cash Ratio | 6.58 | |||||
Days Inventory | 5437.07 | |||||
Days Sales Outstanding | 153.39 | |||||
Days Payable | 7166.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 92.18 | |||||
Operating Margin % | -349.07 | |||||
Net Margin % | -394.08 | |||||
EBITDA Margin % | -387.95 | |||||
FCF Margin % | -311.84 | |||||
OCF Margin % | -295.6 | |||||
ROE % | -18.1 | |||||
ROA % | -15.68 | |||||
ROIC % | -45.28 | |||||
3-Year ROIIC % | 103.39 | |||||
ROC (Joel Greenblatt) % | -75.31 | |||||
ROCE % | -17.12 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 20 | |||||
PS Ratio | 34 | |||||
PB Ratio | 1.68 | |||||
Price-to-Tangible-Book | 1.72 | |||||
EV-to-EBIT | -5.64 | |||||
EV-to-EBITDA | -5.73 | |||||
EV-to-Revenue | 22.24 | |||||
EV-to-FCF | -7.13 | |||||
| Price-to-Net-Current-Asset-Value | 2.39 | |||||
| Price-to-Net-Cash | 3.21 | |||||
Earnings Yield (Greenblatt) % | -17.73 | |||||
FCF Yield % | -8.64 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Beijing Biostar Pharmaceuticals Co Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 36.685 | ||
| EPS (TTM) (HK$) | -0.399 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 95.55 | ||
| 14-Day RSI | 39.53 | ||
| 14-Day ATR (HK$) | 0.098516 | ||
| 20-Day SMA (HK$) | 3.56 | ||
| 12-1 Month Momentum % | -54.11 | ||
| 52-Week Range (HK$) | 2.4 - 9.63 | ||
| Shares Outstanding (Mil) | 389.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Beijing Biostar Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Beijing Biostar Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Beijing Biostar Pharmaceuticals Co Ltd Frequently Asked Questions
What is Beijing Biostar Pharmaceuticals Co Ltd(HKSE:02563)'s stock price today?
The current price of HKSE:02563 is HK$3.40. The 52 week high of HKSE:02563 is HK$9.63 and 52 week low is HK$2.40.
When is next earnings date of Beijing Biostar Pharmaceuticals Co Ltd(HKSE:02563)?
The next earnings date of Beijing Biostar Pharmaceuticals Co Ltd(HKSE:02563) is .
Does Beijing Biostar Pharmaceuticals Co Ltd(HKSE:02563) pay dividends? If so, how much?
Beijing Biostar Pharmaceuticals Co Ltd(HKSE:02563) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Beijing Biostar Pharmaceuticals Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers